AR068918A1 - Productos quimioterapeuticos cristalinos derivados de indazol - Google Patents
Productos quimioterapeuticos cristalinos derivados de indazolInfo
- Publication number
- AR068918A1 AR068918A1 ARP080104544A ARP080104544A AR068918A1 AR 068918 A1 AR068918 A1 AR 068918A1 AR P080104544 A ARP080104544 A AR P080104544A AR P080104544 A ARP080104544 A AR P080104544A AR 068918 A1 AR068918 A1 AR 068918A1
- Authority
- AR
- Argentina
- Prior art keywords
- indazol
- approximately
- crystal
- ethanolate
- methylphenyl
- Prior art date
Links
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 title 1
- 230000000973 chemotherapeutic effect Effects 0.000 title 1
- 239000013078 crystal Substances 0.000 title 1
- HHFAWKCIHAUFRX-UHFFFAOYSA-N ethoxide Chemical compound CC[O-] HHFAWKCIHAUFRX-UHFFFAOYSA-N 0.000 abstract 3
- MPVGZUGXCQEXTM-UHFFFAOYSA-N linifanib Chemical compound CC1=CC=C(F)C(NC(=O)NC=2C=CC(=CC=2)C=2C=3C(N)=NNC=3C=CC=2)=C1 MPVGZUGXCQEXTM-UHFFFAOYSA-N 0.000 abstract 3
- 230000005855 radiation Effects 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000000843 powder Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
Forma cristalina 1 de etanolato de N-[4-(3-amino-1H-indazol-4-il)fenil]-N'-(2-fluoro-5-metilfenil)urea L, formas de elaborarla, formulaciones que la comprenden y elaboradas con la misma y métodos que la utilizan para el tratamiento de pacientes enfermos de cáncer. Reivindicacion 1: La forma cristalina 1 de etanolato de N-[4-(3-amino-1 H-indazol-4-il)fenil]-N'-(2-fluoro-5-metilfenil)urea 1/4 que, cuando se mide a aproximadamente -100°C en el sistema cristalino triclínico en el grupo espacial P1 con radiacion a 0,7107 L, se caracteriza por valores de parámetros reticulares a, b y c de 8,971L +- 0,006L, 11646 L +- 0,008 L y 19,26 L +- 0,01 L, respectivamente, y valores alfa, beta y gamma, de aproximadamente 87,67° +- 0,1°, 90,21° +- 0,1°, y 76,82° +- 0,10 respectivamente. Reivindicacion 2: La forma cristalina 1 de etanolato de N-[4-(3-amino-1H-indazol-4-il)fenil]-N'-(2-fluoro-5-metilfenil)urea L que, cuando se mide a aproximadamente 25°C con radiacion a 1,54178 L, se caracteriza por un patron de difraccion en polvo que tiene valores 2theta de aproximadamente 4,5°, 7,7°, 11,7°, 12,2°, 14,6°, 16,9°, 17,7° y 18,4°, respectivamente.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98131007P | 2007-10-19 | 2007-10-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR068918A1 true AR068918A1 (es) | 2009-12-16 |
Family
ID=40174825
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080104544A AR068918A1 (es) | 2007-10-19 | 2008-10-17 | Productos quimioterapeuticos cristalinos derivados de indazol |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US7994208B2 (es) |
| EP (1) | EP2195300B1 (es) |
| JP (2) | JP5878689B2 (es) |
| KR (1) | KR20100085986A (es) |
| CN (1) | CN101827821B (es) |
| AR (1) | AR068918A1 (es) |
| AU (1) | AU2008312528A1 (es) |
| BR (1) | BRPI0818067A2 (es) |
| CA (1) | CA2699302C (es) |
| CL (1) | CL2008003091A1 (es) |
| CO (1) | CO6280482A2 (es) |
| CR (1) | CR11387A (es) |
| DO (1) | DOP2010000113A (es) |
| EC (1) | ECSP10010182A (es) |
| ES (1) | ES2547878T3 (es) |
| GT (1) | GT201000093A (es) |
| MX (1) | MX2010004288A (es) |
| PA (1) | PA8800301A1 (es) |
| PE (1) | PE20091075A1 (es) |
| RU (1) | RU2010119927A (es) |
| TW (1) | TW200932728A (es) |
| UA (1) | UA99747C2 (es) |
| UY (1) | UY31408A1 (es) |
| WO (1) | WO2009052225A1 (es) |
| ZA (1) | ZA201002180B (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7994208B2 (en) * | 2007-10-19 | 2011-08-09 | Abbott Laboratories | Crystalline chemotherapeutic |
| US20140212355A1 (en) * | 2013-01-28 | 2014-07-31 | Abbott Cardiovascular Systems Inc. | Trans-arterial drug delivery |
| JP7346916B2 (ja) * | 2019-06-04 | 2023-09-20 | 京セラドキュメントソリューションズ株式会社 | 緩衝構造体およびそれを備えた包装材 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102417487A (zh) * | 2003-05-22 | 2012-04-18 | 雅培制药有限公司 | 吲唑、苯并异*唑和苯并异噻唑激酶抑制剂 |
| US7297709B2 (en) * | 2003-05-22 | 2007-11-20 | Abbott Laboratories | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors |
| EP1925941B1 (en) * | 2005-08-01 | 2012-11-28 | Eisai R&D Management Co., Ltd. | Method for prediction of the efficacy of vascularization inhibitor |
| US9006240B2 (en) * | 2005-08-02 | 2015-04-14 | Eisai R&D Management Co., Ltd. | Method for assay on the effect of vascularization inhibitor |
| CN101346128B (zh) | 2005-10-25 | 2013-10-02 | 雅培制药有限公司 | 包含低水溶解度药物的配方及其使用方法 |
| US20070149593A1 (en) * | 2005-12-23 | 2007-06-28 | Alcon, Inc. | PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE |
| WO2008055966A1 (en) * | 2006-11-09 | 2008-05-15 | Abbott Gmbh & Co. Kg | Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor |
| US7994208B2 (en) * | 2007-10-19 | 2011-08-09 | Abbott Laboratories | Crystalline chemotherapeutic |
-
2008
- 2008-10-15 US US12/251,949 patent/US7994208B2/en not_active Expired - Fee Related
- 2008-10-16 CA CA2699302A patent/CA2699302C/en not_active Expired - Fee Related
- 2008-10-16 CN CN200880111903XA patent/CN101827821B/zh not_active Expired - Fee Related
- 2008-10-16 JP JP2010530089A patent/JP5878689B2/ja not_active Expired - Fee Related
- 2008-10-16 UA UAA201006034A patent/UA99747C2/ru unknown
- 2008-10-16 MX MX2010004288A patent/MX2010004288A/es active IP Right Grant
- 2008-10-16 KR KR1020107010989A patent/KR20100085986A/ko not_active Application Discontinuation
- 2008-10-16 EP EP08840138.5A patent/EP2195300B1/en active Active
- 2008-10-16 WO PCT/US2008/080060 patent/WO2009052225A1/en active Application Filing
- 2008-10-16 RU RU2010119927/04A patent/RU2010119927A/ru not_active Application Discontinuation
- 2008-10-16 AU AU2008312528A patent/AU2008312528A1/en not_active Abandoned
- 2008-10-16 BR BRPI0818067 patent/BRPI0818067A2/pt not_active IP Right Cessation
- 2008-10-16 ES ES08840138.5T patent/ES2547878T3/es active Active
- 2008-10-17 TW TW097140031A patent/TW200932728A/zh unknown
- 2008-10-17 CL CL2008003091A patent/CL2008003091A1/es unknown
- 2008-10-17 UY UY31408A patent/UY31408A1/es not_active Application Discontinuation
- 2008-10-17 AR ARP080104544A patent/AR068918A1/es not_active Application Discontinuation
- 2008-10-17 PA PA20088800301A patent/PA8800301A1/es unknown
- 2008-10-17 PE PE2008001782A patent/PE20091075A1/es not_active Application Discontinuation
-
2010
- 2010-03-26 ZA ZA2010/02180A patent/ZA201002180B/en unknown
- 2010-04-14 GT GT201000093A patent/GT201000093A/es unknown
- 2010-04-16 DO DO2010000113A patent/DOP2010000113A/es unknown
- 2010-04-23 CR CR11387A patent/CR11387A/es not_active Application Discontinuation
- 2010-04-27 CO CO10049263A patent/CO6280482A2/es not_active Application Discontinuation
- 2010-05-17 EC EC2010010182A patent/ECSP10010182A/es unknown
-
2014
- 2014-09-29 JP JP2014198628A patent/JP2015042650A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| GT201000093A (es) | 2012-03-12 |
| ES2547878T3 (es) | 2015-10-09 |
| BRPI0818067A2 (pt) | 2015-03-31 |
| EP2195300B1 (en) | 2015-06-24 |
| UY31408A1 (es) | 2009-05-29 |
| UA99747C2 (en) | 2012-09-25 |
| MX2010004288A (es) | 2010-04-30 |
| WO2009052225A1 (en) | 2009-04-23 |
| US20090105326A1 (en) | 2009-04-23 |
| JP2015042650A (ja) | 2015-03-05 |
| CN101827821A (zh) | 2010-09-08 |
| AU2008312528A1 (en) | 2009-04-23 |
| CA2699302C (en) | 2016-06-21 |
| ECSP10010182A (es) | 2010-06-29 |
| TW200932728A (en) | 2009-08-01 |
| PA8800301A1 (es) | 2009-08-26 |
| PE20091075A1 (es) | 2009-08-27 |
| KR20100085986A (ko) | 2010-07-29 |
| JP5878689B2 (ja) | 2016-03-08 |
| CO6280482A2 (es) | 2011-05-20 |
| EP2195300A1 (en) | 2010-06-16 |
| JP2011500704A (ja) | 2011-01-06 |
| CA2699302A1 (en) | 2009-04-23 |
| CN101827821B (zh) | 2012-09-05 |
| US7994208B2 (en) | 2011-08-09 |
| DOP2010000113A (es) | 2010-07-31 |
| CL2008003091A1 (es) | 2009-09-04 |
| ZA201002180B (en) | 2011-10-26 |
| CR11387A (es) | 2010-08-18 |
| RU2010119927A (ru) | 2011-11-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1125214T1 (el) | Ενωσεις ν-((ετ)αρυλμεθυλ)-ετεροαρυλ-καρβοξαμιδιων ως αναστολεις καλλικρεϊνης πλασματος | |
| CR20190124A (es) | Inhibidores de ssao de aminopirimidina | |
| CL2016002033A1 (es) | Compuestos derivados de benzimidazol-2 amino con actividad inhibidora (midh1 r132h); composición farmacéutica, procedimiento de preparación; uso en el tratamiento de tumores gastrointestinales, tumor endocrino, síndrome mielodisplásico, leucemia, tumor de mamas, , metástasis, entre otros. | |
| MX2016008688A (es) | Compuestos terapéuticos inhibidores. | |
| CO6781549A2 (es) | Uso de ligandos sigma en dolor por cáncer de huesos | |
| CL2008000020A1 (es) | Compuestos derivados de 2,4-dianilinopirimidinas sustituidas, inhibidores de proteinas cinasas; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades inflamatorias, diabetes y tumores malignos. | |
| CL2007002431A1 (es) | Compuestos derivados de azabenzotiofenil; composicion farmaceutica; y uso para la inhibicion del crecimiento celular anomalo o de tratamiento de un trastorno hiperproliferativo. | |
| CL2014000775A1 (es) | Compuestos derivados de estra-1,3,5(10),16-tetraen-3-carboxamida; inhibidores de akr1c3; medicamentos que los contienen; y su uso para el tratamiento y/o la prevencion de endometriosis, dismenorrea, acne, alopecia, madurez sexual precoz, cancer de mama, cancer de pulmon, epoc, obesidad y dolor inflamatorio, entre otras. | |
| AR080490A1 (es) | FORMAS CRISTALINAS DE UN INHIBIDOR DE ELASTASA NEUTROFILA, COMPOSICIoN FARMACEUTICA QUE LAS COMPRENDE Y SU USO EN LA FABRICACION DE UN MEDICAMENTO PARA EL TRATAMIENTO DE LA DEFICIENCIA DE ALFA-1-ANTITRIPSINA | |
| DE602007005697D1 (de) | Verwendung von carrageenan zur behandlung von rhinovirus-infektionen | |
| UY38233A (es) | Agentes inhibidores para la tirosina cinasa de bruton | |
| AR068918A1 (es) | Productos quimioterapeuticos cristalinos derivados de indazol | |
| AR086390A1 (es) | Metodo para el tratamiento de malignidades solidas que incluyen malignidades solidas avanzadas o metastasicas | |
| CO6270221A2 (es) | "forma cristalina 2 de n-[4-(3-amino-1h-indazol-4-il)fenil]-n'-(2-fluoro-5-metilfenil)urea". | |
| DOP2010000116A (es) | Productos quimioterapeuticos cristalinos | |
| DOP2010000112A (es) | Productos quimioterapeuticos cristalinos | |
| AR068917A1 (es) | Productos quimioterapeuticos cristalinos derivados de indazol | |
| De Guzman | Livelihood center para sa matatanda | |
| AR066550A1 (es) | Sales monoclorhidrato de un inhibidor de histona deacetilasa | |
| MX2022007874A (es) | Compuestos y derivados de hidroxiestilbeno sustituido, síntesis y usos de los mismos. | |
| EA202190930A1 (ru) | Низкомолекулярные ингибиторы менина | |
| ES2525079A1 (es) | Actividad antiparasitaria de escuaramidas | |
| ECSMU19024959U (es) | Dispositivo flotante de deriva para la agregacion de peces, biodegradable, no enmallante, no envolvente. | |
| TR201719893A2 (tr) | Raloksifen Ve En Az Bir Antipsikotik Ajan İçeren Farmasötik Kombinasyon | |
| PL413048A1 (pl) | Ścierniwo syntetyczne na bazie elektrokorundu oraz sposób jego wytwarzania |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |